Here, we demonstrated the utility of assessing tumor mutational signatures and tumor mutational burden for differentiating MMR‐deficient Lynch‐related from non‐Lynch MMR‐proficient sebaceous lesions which may facilitate improved identification of high‐risk MMR gene mutation carriers. The gene discussed is MRC1; the disease is neoplasm.